Cervicothoracic Sympathetic Block for Post-CCOVID Condition
Official title: A Randomized Controlled Trial for Cervicothoracic Sympathetic Chain Block Against Placebo Saline Injection Evaluation for Post COVID Condition: the CeASE RCT
Run by University Health Network, Toronto · NCT07468604 · Data updated 2026-11-12
This study tests whether a cervicothoracic sympathetic block with local anesthetic can help people who have ongoing post-CCOVID symptoms.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 78 (estimated) |
| Sponsor | University Health Network, Toronto Academic / other |
| Locations | 2 sites (Toronto, Ontario and 1 other locations) |
| Status | Recruiting |
| Started | May 19, 2026 |
| Main results expected | May 20, 2027 |
| Study ends | September 1, 2027 |
| Registry record updated | October 9, 2026 |
| Trial ID | NCT07468604 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18 or older with PCC symptoms lasting at least three months and measurable autonomic dysfunction (COMPASS-31 > 0), stable on PCC medications for at least four weeks.
✕Probably not a fit
Patients without autonomic involvement or who do not respond to the block may see no benefit and could experience procedure-related risks.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 4 interventional trial investigates whether a cervicothoracic sympathetic block improves autonomic symptoms in adults with post-COVID condition. Participants receive 5 mL of 0.25% bupivacaine with epinephrine or saline placebo at the injection site, with randomization and standard safety monitoring. Eligibility focuses on adults with PCC lasting at least three months and measurable autonomic symptoms, who are stable on PCC-related medications. The trial is conducted at two Toronto sites under the University Health Network. Outcomes are expected to inform whether this targeted nerve block can relieve dysautonomia-related PCC symptoms and guide future therapy development.
Why it matters
Potential benefit: If successful, patients may experience reduced autonomic symptoms and improved daily function.
How similar studies have gone: Prior studies of sympatholytic or neuromodulatory approaches in PCC or autonomic dysfunction have shown mixed results; this trial explores a direct local blockade as a novel approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria 1. Age 18 years or older 2. PCC following COVID-19 infection with symptoms lasting for at least three months 3. Ability to read, write, and understand English 4. Quantified autonomic symptoms from at least one domain as reported by the patient on the screener Composite Autonomic Symptom Score (COMPASS-31), i.e. a COMPASS-31 score greater than 0. COMPASS-31 assesses 6 domains of autonomic symptoms: Orthostatic Intolerance, Vasomotor, Secretomotor, Gastrointestinal, Bladder, and Pupillomotor. 5. Patients should be stable on any PCC-related medications for at least four weeks. Exclusion criteria 1. History of co-existing conditions that are a contraindication for CSB: 1. Unilateral vocal cord paralysis; Severe chronic obstructive pulmonary disease (FEV1 between 30-50% of predicted value) 2. Recent myocardial infarction (within the last one year), Cardiac conduction block of any degree 3. Glaucoma 4. Infection or mass at injection site, bleeding disorders 2. Comorbid conditions that could confound study results, such as: 1. Active autoimmune disorders 2. Pre-existing autonomic dysfunction (e.g. POTS, IST, and CRPS) prior to COVID-19 3. Untreated psychiatric conditions (e.g. severe anxiety or PTSD requiring medication adjustments during the study period) 3. Recent history of major surgery or cerebrovascular events within the last three months 4. Allergy to local anesthetic; Inability to extend the neck for any reason (e.g. severe arthritis) 5. History of prior stellate ganglion block
Where it's running
-
Toronto Western Hospital
Toronto, Ontario, Canada Recruiting -
Women's College Hospital
Toronto, Ontario, Canada Not yet recruiting
Study contacts
- Principal investigator: Anuj Bhatia, MD, PhD — University Health Network, Toronto
- Study coordinator: Emad Al Azazi, MD, PhD
- Email: emad.al-azazi@uhn.ca
- Phone: 4166035800
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
See if small fiber neuropathy is common in people with primary Sjögren’s syndrome
This study tests whether small fiber neuropathy is common in adults with primary Sjögren’s syndrome using a quick, non-invasive Sudoscan test.
-
Understanding how ADT for prostate cancer may raise blood pressure and whether nerves or kidneys are involved
This study tests whether nervous system or kidney dysfunction contributes to high blood pressure in men receiving androgen deprivation therapy for prostate cancer.
-
Repetitive transcranial magnetic stimulation to improve heart-autonomic function after stroke
This test adds rTMS to usual neurological rehabilitation to see if it improves heart rate variability, autonomic symptoms, arm strength, and quality of life in people at least three months after a stroke.
-
How blood pressure and heart rate respond to standing and exercise in healthy people and those with high blood pressure
See if blood pressure, heart rate, and arterial stiffness during standing and graded bike exercise differ between healthy young adults and older adults with controlled high blood pressure, including those with orthostatic problems or diabetes.
-
How the sympathetic (fight-or-flight) system works in adults with Down syndrome
This study will test how the sympathetic nervous system responds to stressors like exercise, cold, pain, fear, and caffeine in adults with Down syndrome to see if their heart rate and blood pressure responses are reduced or altered.
-
Polish registry of heart nerve–targeting treatments (cardioneuroablation and cardioneuromodulation)
This registry collects information to see how nerve-targeting heart procedures work for adults with fainting, abnormal heart rhythms, or orthostatic problems.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.